Although, from the recent literature, it can be extrapolated that the ancillary effect of SGLT2 inhibitors present in DM2 patients with HF and CKD could delay the onset of anemia in cardiorenal syndrome, to date, it is not considered a treatment for nephrogenic anemia [69]. This evidence concerns the gene SLC5A2 and chronic kidney disease.